Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

J&J Topamax Expansion Will Include Lennox-Gastaut; "Approvable" At FDA

  • News

Executive Summary

Johnson & Johnson's first step in expanding the Topamax label within the seizure market could be for a Lennox-Gastaut syndrome indication, Group Chairman Joseph Scodari suggested during an analyst R&D day in La Jolla, Calif. May 30.

You may also be interested in...



J&J Topamax Glaucoma Warning, Lennox-Gastaut Indication Added To Label

Johnson & Johnson's Topamax (topiramate) acute myopia and secondary angle glaucoma label warnings will be the subject of a "Dear Healthcare Professional" letter.

J&J Topamax Glaucoma Warning, Lennox-Gastaut Indication Added To Label

Johnson & Johnson's Topamax (topiramate) acute myopia and secondary angle glaucoma label warnings will be the subject of a "Dear Healthcare Professional" letter.

J&J Ultracet Could Clear FDA In May; Ultram Exclusivity Runs To 2003

J&J hopes to receive approval for Ultracet for use in acute pain during May.

Table

View full table

Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS037957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By